Well said! There was some buying interest on Friday after the quarterly report was published.
There was some good stuff in the earnings report and it sounds like the team at Lifeloc is still content with having testing done this year and commercialization by next year.
I was impressed by this line:
“We continue with validation testing utilizing actual human samples obtained through the Colorado School of Public Health at the University of Colorado Anschutz, with results to date confirming SpinDx performance."
And I’m impressed they added fentanyl testing to the SpinDX drug panel. That’s going to prove beneficial in the near future as it continues to be distributed across the country.